scholarly journals Accelerated Hyperfractionated Radiotherapy versus Conventional Fractionation Radiotherapy for Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Bo Zhu ◽  
Changgui Kou ◽  
Wei Bai ◽  
Weiying Yu ◽  
Lili Zhang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Therapeutic Effects ◽  
Cochrane Central Register ◽  
Hyperfractionated Radiotherapy ◽  
Conventional Fractionation ◽  
Treatment Regimens

Objective. The benefits of accelerated hyperfractionated radiotherapy (HART) and conventional fractionation radiotherapy (CFRT) in the treatment of head and neck cancer (HNC) remain controversial. In this study, we analyzed the therapeutic effects of these two treatment regimens to explore whether HART can improve the overall survival (OS) rate and locoregional control (LRC) rate in patients with HNC. Methods. The PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for eligible studies. The OS rate and LRC rate were considered as the efficacy outcomes. I2 was used to test the heterogeneity among studies with a cutoff value of 50%. Potential publication bias was assessed by funnel plots and Egger’s test. We also performed a sensitivity analysis to assess the stability of the results. In this meta-analysis, all analyses were performed using R 3.5.3 software. Results. Twelve qualified articles including a total of 2,935 patients were identified. HART had a significant beneficial effect on OS rate (HR = 0.80, 95% CI: 0.65–0.98). Compared with CFRT, HART demonstrated a significantly higher LRC rate (HR = 0.82, 95% CI: 0.71–0.96). Conclusion. Our meta-analysis showed that HART can significantly improve OS and LRC compared with CFRT in patients with HNC.

scholarly journals Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials

Bionatura ◽  
2020 ◽  
Vol 5 (1) ◽  
pp. 1056-1062
Author(s):  
Carmen Viada ◽  
Aliz M. Vega ◽  
Mayte Robaina ◽  
Aliuska Frías ◽  
Mabel Álvarez ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Sensitivity Analysis ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Phase Ii ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Sufficient Evidence ◽  
Forest Plot ◽  
Controlled Trials

Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: highly expressed protein in malignant tumors of epithelial origin. It has been registered for head and neck tumors since 2002. To determine the effectiveness of Nimotuzumab in head and neck cancer through the combined meta-analysis technique. A search was conducted in PubMed, in an indexed magazine with the words “Nimotuzumab”, “head and neck,” 48 articles published by Cuban and foreign authors were detected between April 1, 2005, and July 31, 2019, in which the results of clinical studies conducted with the monoclonal antibody Nimotuzumab are described. Seven clinical trials conducted in Cuba from 2005-2019 with Nimotuzumab are described; three Phase I / II (with 14, 10 and 10 patients respectively), a Phase II / III with 106 patients, a Phase II with 37 patients, two Phase IV (with 386 and 225 patients each) and a study promoted by the Researcher with 17 patients. From these studies, the three controlled trials were selected by the PRISMA flow chart. The meta-analysis consisted of the construction of the Forest Plot graph, the sensitivity analysis and the cumulative analysis. The meta-analysis shows favorable results for Nimotuzumab, without heterogeneity (I2 = 0%). The sensitivity analysis reveals that the test that differs most from the others is Phase II / III. The cumulative analysis indicates that after the second trial, there is already sufficient evidence.

Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer—a meta-analysis

2019 ◽  
Vol 195 (12) ◽  
pp. 1041-1049 ◽  
Author(s):  
Jan Haussmann ◽  
Bálint Tamaskovics ◽  
Edwin Bölke ◽  
Freddy-Joel Djiepmo-Njanang ◽  
Kai Kammers ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Advanced Head ◽  
Hyperfractionated Radiotherapy

scholarly journals Nanoparticle-Based Chemotherapy Formulations for Head and Neck Cancer: A Systematic Review and Perspectives

Nanomaterials ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 1938
Author(s):  
Jefferson Muniz de Lima ◽  
Paulo Rogerio Bonan ◽  
Danyel Elias da Cruz Perez ◽  
Michael Hier ◽  
Moulay A. Alaoui-Jamali ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Side Effects ◽  
Head And Neck ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Basic Research ◽  
Cochrane Central Register ◽  
Level Of Evidence ◽  
Mortality And Morbidity

Head and neck cancer (HNC) is a complex and heterogeneous disease associated with high mortality and morbidity worldwide. Standard therapeutic management of advanced HNC, which is based on radiotherapy often combined with chemotherapy, has been hampered by severe long-term side effects. To overcome these side effects, tumor-selective nanoparticles have been exploited as a potential drug delivery system to improve HNC therapy. A combination of MEDLINE, EMBASE, Cochrane Oral Health Group’s Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov from inception up to June 2020 was used for this systematic review. A total of 1747 published manuscripts were reviewed and nine relevant references were retrieved for analysis, while eight of them were eligible for meta-analysis. Based on these studies, the level of evidence about the efficacy of nanoformulation for HNC therapy on tumor response and adverse side effects (SAE) was low. Even though basic research studies have revealed a greater promise of nanomaterial to improve the outcome of cancer therapy, none of them were translated into clinical benefits for HNC patients. This systematic review summarized and discussed the recent progress in the development of targeted nanoparticle approaches for HNC management, and open-up new avenues for future perspectives.

scholarly journals Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Ofra Novoplansky ◽  
Sankar Jagadeeshan ◽  
Ohad Regev ◽  
Idan Menashe ◽  
Moshe Elkabets
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Clinical Features ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Anatomical Site ◽  
Cochrane Central Register ◽  
Kras Mutations ◽  
Ras Mutations ◽  
Hpv Status

Importance: There is considerable variation among different studies for the prevalence of RAS mutations in head and neck cancer (HNC) patients. In light of the development of RAS inhibitors, a reliable assessment of the prevalence of RAS mutations and their correlation with the clinical features of patients with HNC is crucially needed. Objective: To assess the worldwide prevalence of HRAS, KRAS, and NRAS mutations in HNC in the relation to geographical region, anatomical site(s) of the tumor(s) and clinical features. Data Sources: A systematic search of the PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials databases was performed to identify studies published since January 2000. Data were analyzed between June and September 2021. Study Selection: Studies that included mutational analyses of at least one of the target genes and reported the prevalence and frequency of mutations as an outcome measure were included. Studies including less than ten patients or were conducted before year 2000 were excluded. Data Extraction and Synthesis: Two researchers independently reviewed the literature according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. Random-effects models were applied to results with high heterogeneity. Otherwise, fixed-effects models were used for the analyses. Dichotomous variables were pooled as odds ratios (OR). Main Outcome(s) and Measure(s): The primary outcome was mutation prevalence. Secondary outcomes included the location of the mutated codon and amino acid substitution. Results: The estimated mutation rate is highest for HRAS (7%), followed by KRAS (2.89%) and NRAS (2.20%). HRAS prevalence in South Asia (15.28%) is twice as high as the global estimate. HRAS mutations are more prevalent in oral cavity and salivary gland tumors. In contrast, KRAS mutations are found more frequently in sinonasal tumors, and NRAS mutations are found chiefly in tumors of the nasopharynx. OR analyses show a significant association between HRAS mutations and a high tumor stage (OR=3.63). In addition, there is a significant association between HPV-positive status and KRAS mutations (OR=2.09). Conclusions and Relevance: RAS mutations occur in a subset of HNC patients and their prevalence varies according to geography, tumors anatomical site, stage, and HPV status. This meta-analysis provides support for their potential as viable therapeutic targets in HNC patients.

Sign in / Sign up

Export Citation Format

Share Document